Engineered mRNA nanoparticles reprogram fatty liver and boost liver cancer immunotherapy in animal models

Metabolic dysfunction-associated fatty liver disease (MAFLD) is increasingly common and is a leading cause of hepatocellular carcinoma (HCC). Metabolic stress in the fatty liver produces an abnormal immune microenvironment that promotes disease progression and may blunt immunotherapy. No drugs currently target this environment directly.

The team designed a lipid nanoparticle, Def-LNP, that incorporates vitamin E-derived phosphatidylcholine. The aim was to buffer the oxidative conditions of the diseased liver so that mRNA delivered to hepatocytes would be expressed in a sustained, localized way. They compared it with a commercially used LNP formulation and assessed delivery, stability, and safety in mice, pigs, and nonhuman primates.

Using clinical samples, the authors found a pronounced association between T cell protein tyrosine phosphatase (TCPTP) and MAFLD. They then delivered TCPTP-encoding mRNA via Def-LNP. In MAFLD mice, this suppressed STAT signaling in hepatocytes and drove metabolic reprogramming and immune reconfiguration, an effect the authors say is lacking in conventional mRNA protein-replacement approaches. The treatment eliminated steatohepatitis, impeded hepatocarcinogenesis, and improved HCC responses to a cancer vaccine and to immune checkpoint blockade.

If these results translate, the approach could pair metabolic liver repair with immunotherapy, addressing a setting where immune treatments often underperform. It also illustrates that the nanoparticle's composition can be tuned to the diseased tissue rather than serving as a passive carrier.

Caveats: this summary is based only on the abstract. The efficacy data come from preclinical animal models, and the larger-animal work as described addresses delivery, stability, and safety rather than efficacy. Human benefit, long-term safety, repeat dosing, and durability remain untested.